Pfizer Announces Seven-Year Follow-Up Results for Lorbrena
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating Lorbrena versus Xalkori in people with previously untreated, anaplastic lymphoma kinase-positive advanced or metastatic non-small cell lung cancer, NSCLC. At seven years, patients treated with Lorbrena had a 55% likelihood of remaining alive without disease progression compared to 3% in the Xalkori treatment arm. Further, an updated analysis at seven years of median follow-up showed that investigator-assessed median progression-free survival, PFS, had not been reached with Lorbrena, with an estimated Hazard Ratio of 0.19, representing an 81% reduction in the risk of disease progression or death compared to Xalkori. Full results from the analysis will be presented today in an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in Annals of Oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.140
Low
24.00
Averages
28.56
High
35.00
Current: 26.140
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Rise on Ceasefire Agreement and AI Optimism
- Ceasefire Agreement Impact: The temporary 60-day ceasefire agreement between the US and Iran alleviated energy price concerns for oil-importing nations, contributing to a 1.2% rise in the S&P 500 index.
- AI-Driven Optimism: Renewed optimism surrounding artificial intelligence and related technologies propelled the Nasdaq index up by 2%, indicating strong performance in tech stocks and a recovery in investor confidence.
- European Market Decline: In contrast to the US gains, European equities fell, with the STOXX index down 0.5%, reflecting concerns over the eurozone economic outlook, particularly after lower-than-expected inflation rates in Germany and France.
- Asian Market Divergence: Chinese markets dropped by 1.4%, while Japan's Nikkei 225 rose by 2.2%, highlighting a lack of synchronization in regional economic recovery, especially given Japan's strong retail sales and industrial output figures.
See More
Pfizer's BRAFTOVI Clinical Trial Progress Update
- Significant Efficacy Improvement: In Cohort 3 of the BREAKWATER trial, the BRAFTOVI combination therapy achieved a median progression-free survival (PFS) of 15.2 months, nearly doubling the comparator's 8.3 months, indicating a potential shift in treatment paradigms.
- Survival Rate Enhancement: Patients receiving the BRAFTOVI regimen experienced a 44% reduction in death risk, with an expected 72% survival rate at 18 months compared to 54.5% in the comparator group, highlighting the clinical significance of this combination therapy in extending survival.
- Stable Safety Profile: The safety profile of BRAFTOVI in combination with other agents remained consistent with known drug characteristics, with no new safety signals identified; 70.4% of patients experienced grade 3 adverse events, lower than the 80.9% in the comparator group, suggesting better tolerability.
- Treatment Discontinuation Rates: Treatment discontinuation due to adverse events was reported in 15.5% of patients on the BRAFTOVI regimen versus 10.3% for the comparator, indicating a need to monitor patient tolerability and treatment continuity in clinical practice.
See More
New Lung Cancer Drug ivonescimab Significantly Extends Survival
- Clinical Trial Results: The experimental drug ivonescimab from Akeso and Summit Therapeutics demonstrated a 34% reduction in death risk in late-stage trials, extending median survival by four months for patients with squamous non-small-cell lung cancer when combined with chemotherapy, indicating its potential in difficult-to-treat populations.
- Global Research Plans: The results from the Phase 3 trial conducted in China have garnered attention, and while a global Phase 3 study is ongoing, the applicability of the Chinese data to other populations remains uncertain, highlighting implications for future market dynamics.
- Market Reaction: Since Summit Therapeutics announced ivonescimab's superiority over Keytruda in a separate trial, its stock has surged nearly 600%, yet recent declines due to concerns over global efficacy reflect investor divisions regarding the drug's prospects.
- Safety Considerations: The trial revealed a bleeding incidence of nearly 25% in the ivonescimab group, double that of the control group, raising safety concerns despite fewer severe cases, which may impact market acceptance.
See More
Analysts' Negative Outlook on Pfizer
- Analyst Rating Discrepancy: Among 29 analysts, only 2 have a strong buy rating for Pfizer, with 9 at buy, while the rest are hold or sell, indicating over 60% of analysts suggest a cautious view, reflecting a negative market perception of the company.
- Stock Price Decline Impact: Pfizer's stock has fallen over 50% from its 2021 peak, leading to investor disappointment regarding its business outlook, particularly with upcoming patent expirations that will significantly impact revenue from key drugs like Eliquis and Vyndaqel.
- New Drug Development Challenges: Pfizer's decision to drop its internally developed GLP-1 drug in the first half of 2025 has hindered its entry into a high-demand drug category, resulting in diminished investor confidence in its future product pipeline and negatively affecting the company's market image.
- Rising Dividend Yield: Despite Pfizer's dividend yield rising to 6.6%, well above the market average of 1.1%, its payout ratio exceeds 100%, yet the company remains committed to supporting dividend payments, demonstrating a determination to maintain shareholder returns during challenging times.
See More
Pfizer Faces Challenges but Long-Term Investment Opportunities Emerge
- Analyst Rating Divergence: Pfizer currently has 29 analysts covering it, with only 2 rating it as a strong buy and 9 as buy, while the rest are hold or sell, indicating that over 60% of analysts suggest a cautious view, reflecting widespread pessimism about its future performance.
- Significant Stock Decline: Pfizer's stock has fallen over 50% from its 2021 peak, indicating investor disappointment in its business outlook, particularly as several key drugs are set to lose patent protection by 2028, which will significantly impact the company's revenue and profits.
- Rising Dividend Yield: Pfizer's dividend yield has climbed to 6.6%, well above the market average of 1.1% and the average for other drug makers at 1.7%, and despite a payout ratio exceeding 100%, the company maintains its commitment to support dividend payments, showcasing its financial resilience during tough times.
- New Drug Development Progress: Although Pfizer had to drop its internally developed GLP-1 drug in the first half of 2025, it acquired a company with a more promising GLP-1 candidate, indicating that Pfizer is actively advancing new vaccines, migraine medications, and oncology drugs, striving to navigate current challenges.
See More
Pfizer's TALZENNA and XTANDI Show Promising Results in Prostate Cancer Study
- Clinical Trial Results: Pfizer's TALAPRO-3 study revealed that the combination of TALZENNA and XTANDI resulted in a 52% reduction in the risk of radiographic progression or death, with a three-year radiographic progression-free survival (rPFS) rate of 77%, significantly outperforming the placebo group at 56%, highlighting the clinical significance of this combination in treating metastatic prostate cancer.
- Survival Rate Analysis: Although the median overall survival (OS) has not yet been reached, interim results indicate a strong trend towards improved OS with the TALZENNA and XTANDI combination, suggesting potential in extending patient survival, with formal assessment planned for the final analysis.
- Safety Assessment: The safety profile of TALZENNA and XTANDI in the TALAPRO-3 study was consistent with known drug characteristics, with no new safety signals identified; however, 51% of patients experienced anemia as a treatment-emergent adverse event, which was manageable through dose modifications and supportive care, indicating the tolerability of this combination.
- Patient Subgroup Consistency: The rPFS benefit of TALZENNA and XTANDI remained consistent across various patient and disease subgroups, including those with BRCA and non-BRCA gene mutations, with three-year rPFS rates of 77% for BRCA mutation patients and 76% for non-BRCA mutation patients, further supporting the broad applicability of this treatment regimen.
See More
US Stocks Rise on Ceasefire Agreement and AI Optimism
- Ceasefire Agreement Impact: The temporary 60-day ceasefire agreement between the US and Iran alleviated energy price concerns for oil-importing nations, contributing to a 1.2% rise in the S&P 500 index.
- AI-Driven Optimism: Renewed optimism surrounding artificial intelligence and related technologies propelled the Nasdaq index up by 2%, indicating strong performance in tech stocks and a recovery in investor confidence.
- European Market Decline: In contrast to the US gains, European equities fell, with the STOXX index down 0.5%, reflecting concerns over the eurozone economic outlook, particularly after lower-than-expected inflation rates in Germany and France.
- Asian Market Divergence: Chinese markets dropped by 1.4%, while Japan's Nikkei 225 rose by 2.2%, highlighting a lack of synchronization in regional economic recovery, especially given Japan's strong retail sales and industrial output figures.
See More
Pfizer's BRAFTOVI Clinical Trial Progress Update
- Significant Efficacy Improvement: In Cohort 3 of the BREAKWATER trial, the BRAFTOVI combination therapy achieved a median progression-free survival (PFS) of 15.2 months, nearly doubling the comparator's 8.3 months, indicating a potential shift in treatment paradigms.
- Survival Rate Enhancement: Patients receiving the BRAFTOVI regimen experienced a 44% reduction in death risk, with an expected 72% survival rate at 18 months compared to 54.5% in the comparator group, highlighting the clinical significance of this combination therapy in extending survival.
- Stable Safety Profile: The safety profile of BRAFTOVI in combination with other agents remained consistent with known drug characteristics, with no new safety signals identified; 70.4% of patients experienced grade 3 adverse events, lower than the 80.9% in the comparator group, suggesting better tolerability.
- Treatment Discontinuation Rates: Treatment discontinuation due to adverse events was reported in 15.5% of patients on the BRAFTOVI regimen versus 10.3% for the comparator, indicating a need to monitor patient tolerability and treatment continuity in clinical practice.
See More
New Lung Cancer Drug ivonescimab Significantly Extends Survival
- Clinical Trial Results: The experimental drug ivonescimab from Akeso and Summit Therapeutics demonstrated a 34% reduction in death risk in late-stage trials, extending median survival by four months for patients with squamous non-small-cell lung cancer when combined with chemotherapy, indicating its potential in difficult-to-treat populations.
- Global Research Plans: The results from the Phase 3 trial conducted in China have garnered attention, and while a global Phase 3 study is ongoing, the applicability of the Chinese data to other populations remains uncertain, highlighting implications for future market dynamics.
- Market Reaction: Since Summit Therapeutics announced ivonescimab's superiority over Keytruda in a separate trial, its stock has surged nearly 600%, yet recent declines due to concerns over global efficacy reflect investor divisions regarding the drug's prospects.
- Safety Considerations: The trial revealed a bleeding incidence of nearly 25% in the ivonescimab group, double that of the control group, raising safety concerns despite fewer severe cases, which may impact market acceptance.
See More
Analysts' Negative Outlook on Pfizer
- Analyst Rating Discrepancy: Among 29 analysts, only 2 have a strong buy rating for Pfizer, with 9 at buy, while the rest are hold or sell, indicating over 60% of analysts suggest a cautious view, reflecting a negative market perception of the company.
- Stock Price Decline Impact: Pfizer's stock has fallen over 50% from its 2021 peak, leading to investor disappointment regarding its business outlook, particularly with upcoming patent expirations that will significantly impact revenue from key drugs like Eliquis and Vyndaqel.
- New Drug Development Challenges: Pfizer's decision to drop its internally developed GLP-1 drug in the first half of 2025 has hindered its entry into a high-demand drug category, resulting in diminished investor confidence in its future product pipeline and negatively affecting the company's market image.
- Rising Dividend Yield: Despite Pfizer's dividend yield rising to 6.6%, well above the market average of 1.1%, its payout ratio exceeds 100%, yet the company remains committed to supporting dividend payments, demonstrating a determination to maintain shareholder returns during challenging times.
See More
Pfizer Faces Challenges but Long-Term Investment Opportunities Emerge
- Analyst Rating Divergence: Pfizer currently has 29 analysts covering it, with only 2 rating it as a strong buy and 9 as buy, while the rest are hold or sell, indicating that over 60% of analysts suggest a cautious view, reflecting widespread pessimism about its future performance.
- Significant Stock Decline: Pfizer's stock has fallen over 50% from its 2021 peak, indicating investor disappointment in its business outlook, particularly as several key drugs are set to lose patent protection by 2028, which will significantly impact the company's revenue and profits.
- Rising Dividend Yield: Pfizer's dividend yield has climbed to 6.6%, well above the market average of 1.1% and the average for other drug makers at 1.7%, and despite a payout ratio exceeding 100%, the company maintains its commitment to support dividend payments, showcasing its financial resilience during tough times.
- New Drug Development Progress: Although Pfizer had to drop its internally developed GLP-1 drug in the first half of 2025, it acquired a company with a more promising GLP-1 candidate, indicating that Pfizer is actively advancing new vaccines, migraine medications, and oncology drugs, striving to navigate current challenges.
See More
Pfizer's TALZENNA and XTANDI Show Promising Results in Prostate Cancer Study
- Clinical Trial Results: Pfizer's TALAPRO-3 study revealed that the combination of TALZENNA and XTANDI resulted in a 52% reduction in the risk of radiographic progression or death, with a three-year radiographic progression-free survival (rPFS) rate of 77%, significantly outperforming the placebo group at 56%, highlighting the clinical significance of this combination in treating metastatic prostate cancer.
- Survival Rate Analysis: Although the median overall survival (OS) has not yet been reached, interim results indicate a strong trend towards improved OS with the TALZENNA and XTANDI combination, suggesting potential in extending patient survival, with formal assessment planned for the final analysis.
- Safety Assessment: The safety profile of TALZENNA and XTANDI in the TALAPRO-3 study was consistent with known drug characteristics, with no new safety signals identified; however, 51% of patients experienced anemia as a treatment-emergent adverse event, which was manageable through dose modifications and supportive care, indicating the tolerability of this combination.
- Patient Subgroup Consistency: The rPFS benefit of TALZENNA and XTANDI remained consistent across various patient and disease subgroups, including those with BRCA and non-BRCA gene mutations, with three-year rPFS rates of 77% for BRCA mutation patients and 76% for non-BRCA mutation patients, further supporting the broad applicability of this treatment regimen.
See More
